🟢 Incyte is trading 6.2% up in pre-market after Ontario announced accelerated public funding for MINJUVI

Incyte is trading $129.00 (+6.20%) in pre-market after Ontario announced accelerated public funding for MINJUVI in relapsed or refractory follicular lymphoma.

• Recent healthcare-conference updates and the expanded access announcement appear to be supporting sentiment despite weaker U.S. equity futures.
• No pre-market volume was provided, so activity intensity cannot be assessed.